Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient’s plasma – a prospective trial

por Hasenburg, A., Eichkorn, D., Vosshagen, F., Obermayr, E., Geroldinger, A., Zeillinger, R., Bossart, M.
Publicado 2021

Presence of endothelial calcium-dependent nitric oxide synthase in breast apocrine metaplasia.

por Tschugguel, W., Knogler, W., Czerwenka, K., Mildner, M., Weninger, W., Zeillinger, R., Huber, J. C.
Publicado 1996

Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer.

por Obermair, A., Tempfer, C., Hefler, L., Preyer, O., Kaider, A., Zeillinger, R., Leodolter, S., Kainz, C.
Publicado 1998

Expression of variant forms of the MUC1 gene correlates with the invasiveness of breast cancer cells

por Zeillinger, R, Schmid, B, Tong, D, Fasching, B, Schiebl, I, Stimpfl, M, Obermair, A, Leodolter, S
Publicado 2000

DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.

por Courjal, F., Cuny, M., Rodriguez, C., Louason, G., Speiser, P., Katsaros, D., Tanner, M. M., Zeillinger, R., Theillet, C.
Publicado 1996

Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study.

por Wiltschke, C., Krainer, M., Budinsky, A. C., Berger, A., Müller, C., Zeillinger, R., Speiser, P., Kubista, E., Eibl, M., Zielinski, C. C.
Publicado 1995

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway

por Pils, D, Pinter, A, Reibenwein, J, Alfanz, A, Horak, P, Schmid, B C, Hefler, L, Horvat, R, Reinthaller, A, Zeillinger, R, Krainer, M
Publicado 2007

A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignancies.

por Speiser, P., Gharehbaghi-Schnell, E., Eder, S., Haid, A., Kovarík, J., Nenutil, R., Sauter, G., Schneeberger, C. H., Vojtesek, B., Wiltschke, C. H., Zeillinger, R.
Publicado 1996

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer

por Hofstetter, G, Berger, A, Schuster, E, Wolf, A, Hager, G, Vergote, I, Cadron, I, Sehouli, J, Braicu, E I, Mahner, S, Speiser, P, Marth, C, Zeimet, A G, Ulmer, H, Zeillinger, R, Concin, N
Publicado 2011